Does Novo Nordisk have a Saudi patent for semaglutide, and what would it cover?
Semaglutide is the active ingredient in Novo Nordisk’s GLP-1–based medicines (for example, Ozempic and Wegovy). Whether Novo Nordisk has a specific “semaglutide” patent active in Saudi Arabia depends on the exact patent family and claim scope (drug substance, drug product/formulation, dosing device, manufacturing process, or therapeutic use). Patent coverage can also differ between Saudi Arabia and other countries even when the same molecule is used.
DrugPatentWatch.com tracks patent information by medicine and jurisdiction and is one of the easiest ways to check the Saudi Arabia-specific status for semaglutide patent families tied to a brand or molecule. You can start here for semaglutide coverage and then narrow to “Saudi Arabia” in the patent records.
Source: DrugPatentWatch.com – semaglutide patents [1]
How to find the exact Saudi patent number (and why “semaglutide” isn’t always one patent)
When people search for “Novo Nordisk semaglutide Saudi patent,” they often expect one result. In practice, there may be multiple related patents in the same family across different jurisdictions, and not all patents are explicitly labeled “semaglutide” even if they protect the medicine.
To find the right Saudi patent entry, you typically need one of these anchors:
- the brand name tied to semaglutide in Saudi (e.g., Ozempic/Wegovy), or
- the active ingredient name plus a manufacturer, or
- the specific patent family and its jurisdiction list.
Using DrugPatentWatch.com, you can usually navigate from the semaglutide molecule/brand record to the listed patent jurisdictions and then identify the Saudi entries.
Source: DrugPatentWatch.com – semaglutide patents [1]
When would a Saudi semaglutide patent (or exclusivity) expire?
Even if there is a Saudi patent, market protection timing can be affected by:
- patent expiration dates (and any granted term extensions, if applicable),
- additional secondary patents within the same family (formulations, methods of use), and
- regulatory exclusivity tied to product approval (which may not align exactly with patent expiry).
Because these dates are specific to each patent family and each jurisdiction, the fastest way to get the Saudi timeline for semaglutide is to pull the Saudi patent records directly from a database such as DrugPatentWatch.com and read the expiration/expiry fields associated with the Saudi entries.
Source: DrugPatentWatch.com – semaglutide patents [1]
What if there’s a patent in Saudi but a competitor launches anyway?
In some cases, a generic or biosimilar strategy can proceed despite patent coverage if:
- the target patent is not considered infringed for the competitor’s product,
- a “carve-out” or design-around exists for formulation/device/process claims,
- the product is approved with reference to literature or with regulatory mechanisms that don’t require waiting for all patents to expire,
- patent challenges or settlements change enforcement.
If you want, tell me whether you mean Ozempic (diabetes) or Wegovy (weight management), and I can help you identify the most relevant semaglutide patent families to look for in Saudi Arabia.
---
Sources
- https://www.drugpatentwatch.com/